Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Urate crystals alone are required but not sufficient to trigger gout flares; they can also be modulated by environmental, metabolic, genetic and epigenetic factors. Avoiding large variation in urate levels, maintaining prophylaxis until crystal clearance and initiating low-dose urate-lowering therapy are efficient strategies for disease management.
In the phase III SELECT-GCA trial, upadacitinib at a dose of 15 mg daily was superior to placebo with respect to achievement of sustained remission of giant cell arteritis at 52 weeks.
In the MESKO clinical trial, treatment with low-dose methotrexate did not improve pain or joint inflammation in individuals with inflammatory knee osteoarthritis.
A simple blood test that can diagnose or predict one’s risk for autoimmune diseases would revolutionize medicine and transform patient care. Published in Science, Zaslavsky et al. advance this vision with a powerful machine learning framework that leverages immune receptor sequences from T cells and B cells for disease classification.
Systemic lupus erythematosus is characterized by altered metabolic profiles and changes in immune cell metabolism. The authors review these changes and discuss how interventions that target metabolic processes might provide treatment options in systemic lupus erythematosus.
This Review discusses the advances and challenges of managing antineutrophil cytoplasmic antibody-associated vasculitis. The authors discuss current treatment options, emerging therapies and unmet needs in the management of this disease.
This Review discusses the clinical features, pathogenesis, diagnosis and management of monogenic forms of vasculitis. The authors emphasize that increased awareness of these rare diseases could aid earlier diagnosis and better, more-targeted treatment options for patients.
In this Consensus Statement, an international group of experts and patient representatives validates and endorses the transition from the term ‘Sjögren syndrome’ to ‘Sjögren disease’, and issue several additional recommendations regarding the nomenclature of this disorder.
